News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
21,928 Results
Type
Article (1031)
Company Profile (2)
Press Release (20895)
Section
Business (11138)
Career Advice (19)
Deals (1448)
Drug Development (2019)
FDA (343)
Job Trends (510)
News (14073)
Policy (554)
Tag
Academia (17)
Allergies (3)
Alliances (720)
ALS (1)
Alzheimer's disease (13)
Antibody-drug conjugate (ADC) (5)
Approvals (348)
Artificial intelligence (8)
Autoimmune disease (6)
Bankruptcy (8)
Best Places to Work (387)
Biosimilars (2)
Biotechnology (2)
Bladder cancer (16)
Brain cancer (1)
Breast cancer (11)
Cancer (131)
Cardiovascular disease (8)
Career advice (16)
CAR-T (2)
Cell therapy (7)
Clinical research (1840)
Collaboration (20)
Compensation (8)
COVID-19 (44)
CRISPR (1)
C-suite (3)
Cystic fibrosis (2)
Data (186)
Depression (5)
Diabetes (11)
Diagnostics (229)
Digital health (2)
Drug discovery (2)
Duchenne muscular dystrophy (4)
Earnings (10657)
Events (1946)
Executive appointments (6)
FDA (503)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (1)
Frontotemporal dementia (1)
Funding (6)
Gene editing (2)
Gene therapy (4)
GLP-1 (22)
Government (48)
Guidances (125)
Healthcare (573)
Huntington's disease (2)
IgA nephropathy (3)
Immunology and inflammation (8)
Indications (3)
Infectious disease (51)
Inflammatory bowel disease (2)
Influenza (1)
Intellectual property (3)
Interviews (2)
IPO (1157)
Job creations (118)
Job search strategy (15)
Kidney cancer (2)
Labor market (2)
Layoffs (5)
Legal (103)
Liver cancer (2)
Lung cancer (28)
Lymphoma (9)
Manufacturing (4)
MASH (8)
Medical device (487)
Medtech (489)
Mergers & acquisitions (295)
Metabolic disorders (31)
Multiple sclerosis (3)
NASH (1)
Neurodegenerative disease (2)
Neuropsychiatric disorders (3)
Neuroscience (43)
NextGen: Class of 2025 (175)
Non-profit (40)
Obesity (9)
Ovarian cancer (2)
Pain (3)
Pancreatic cancer (2)
Parkinson's disease (2)
Patents (3)
Patient recruitment (2)
Peanut (1)
People (680)
Pharmacy benefit managers (1)
Phase I (377)
Phase II (788)
Phase III (812)
Pipeline (453)
Policy (2)
Postmarket research (63)
Preclinical (159)
Press Release (40)
Prostate cancer (16)
Radiopharmaceuticals (3)
Rare diseases (9)
Real estate (98)
Regulatory (447)
Reports (5)
Research institute (22)
Resumes & cover letters (4)
RSV (3)
Schizophrenia (10)
Sickle cell disease (1)
Special edition (2)
Spinal muscular atrophy (1)
Startups (63)
Tariffs (2)
Vaccines (23)
Weight loss (5)
Women's health (4)
Date
Last 7 days (8)
Last 30 days (215)
Last 365 days (1270)
2025 (1238)
2024 (1446)
2023 (1544)
2022 (1792)
2021 (1778)
2020 (1695)
2019 (1188)
2018 (841)
2017 (669)
2016 (286)
2015 (6275)
2014 (410)
2013 (187)
2012 (207)
2011 (323)
2010 (319)
Location
Africa (32)
Alabama (2)
Arizona (7)
Asia (1321)
Australia (165)
California (391)
Canada (96)
China (31)
Colorado (28)
Connecticut (28)
Delaware (19)
Europe (2959)
Florida (66)
Georgia (17)
Illinois (36)
Indiana (34)
Iowa (1)
Japan (9)
Kansas (7)
Kentucky (2)
Louisiana (6)
Maine (2)
Maryland (50)
Massachusetts (218)
Michigan (14)
Minnesota (24)
Missouri (6)
Montana (4)
Nevada (8)
New Hampshire (5)
New Jersey (291)
New York (104)
North Carolina (60)
Northern California (213)
Ohio (9)
Pennsylvania (104)
South America (44)
Southern California (155)
Tennessee (1)
Texas (57)
United States (1654)
Utah (70)
Virginia (1)
Washington D.C. (2)
Washington State (29)
Wisconsin (2)
21,928 Results for "154".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Akeso Announces First Patient Dosed in Phase I Trial of Personalized mRNA Vaccine AK154 as Monotherapy or in Combination with Cadonilimab or Ivonescimab for Adjuvant Treatment of Pancreatic Cancer
November 10, 2025
·
4 min read
Press Releases
Novo Nordisk’s sales increased by 16% in Danish kroner and by 18% at constant exchange rates to DKK 154.9 billion in the first six months of 2025
August 6, 2025
·
4 min read
BioCapital
Maryland Stem Cell Research Commission Announces $15.4 Million in Awards to Accelerate Cures
The Maryland Stem Cell Research Commission is pleased to announce the next round of awards granting a total of more than $15.4 million.
May 14, 2024
·
6 min read
Press Releases
Teknova Announces Closing of $15.4 Million Private Placement
July 15, 2024
·
4 min read
Business
Arcturus Therapeutics and CSL Announce European Medicines Agency Validates Marketing Authorization Application for ARCT-154 Vaccine to Prevent COVID-19
Arcturus Therapeutics and CSL Announce European Medicines Agency Validates Marketing Authorization Application for ARCT-154 Vaccine to Prevent COVID-19.
September 5, 2023
·
6 min read
Biotech Beach
Japan’s Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics’ ARCT-154, the first Self-Amplifying mRNA vaccine approved for COVID in adults
Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) and Arcturus Therapeutics today announced that Japan’s Ministry of Health, Labor and Welfare (MHLW) granted approval for ARCT-154, a self-amplifying mRNA (sa-mRNA) COVID-19 vaccine for initial vaccination and booster for adults 18 years and older.
November 28, 2023
·
5 min read
Biotech Beach
CSL and Arcturus Therapeutics’ ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster
Global biotechnology leader CSL and Arcturus Therapeutics announced the publication in Lancet Infectious Diseases of a Phase 3 study showing that a booster dose of ARCT-154, a novel, self-amplifying messenger RNA vaccine, elicited a numerically higher immune response against the original Wuhan-Hu-1 virus strain, and a superior immune response against Omicron BA.4/5 subvariant of SARS-CoV-2 virus compared to a booster dose of the conventional mRNA vaccine Comirnaty®.
December 21, 2023
·
8 min read
Smart Patches Market Size to Reach US$ 15.4 Billion by 2030
According to the report, the smart patches market size was valued at US$ 8.2 Bn in 2020 and is expected to reach US$ 15.4 billion by 2030, expanding growth at a CAGR of 6.1% from 2021 to 2030.
June 3, 2022
·
4 min read
Biotech Beach
Arcturus Reports Durability Data Against Omicron Variants, Including BA.5, at Six-Month Timepoint Following Booster with ARCT-154 COVID-19 Vaccine
Arcturus Therapeutics Holdings Inc. today announced updated data from its ongoing ARCT-154 booster clinical trial.
August 18, 2022
·
7 min read
Drug Development
Arcturus Reports Strong Three-Month Durability Results from ARCT-154 Booster Trial
Arcturus Therapeutics Holdings Inc. today provided updated data from its Phase 1/2 booster clinical trial showing durability of antibody response with ARCT-154 for at least three months after low-dose (5 mcg) booster.
May 5, 2022
·
7 min read
1 of 2,193
Next
